Company intelligence / Profile preview

QyA Bio

South San Francisco, California, United States

Ownership: Private
Development stage: Other

Overview

QyA Bio is a preclinical-stage biotechnology company focused on developing next-generation small molecule therapies for autoimmune and inflammatory diseases. The company leverages a proprietary discovery platform to identify and modulate pathways intrinsic to regulatory T cells (Tregs), aiming to restore immune homeostasis. Backed by The Column Group, QyA Bio is advancing a pipeline of oral candidates designed to enhance Treg stability and suppressive function. Its approach seeks to provide more effective and convenient treatment options for patients with chronic immune-mediated conditions.

Therapeutic areas: Immunology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on QyA Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on QyA Bio.

Explore the full profile